Transgene has received the approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to proceed with a Phase 1/2a clinical trial of TG6002 administered by intrahepatic artery (IHA) infusion in colorectal cancer patients with unresectable liver metastases (CRLM).
GlaxoSmithKline (GSK) said that a phase 3 trial evaluating its polymerase (PARP) inhibitor Zejula (niraparib) as a maintenance therapy for first-line ovarian cancer following platinum-based chemotherapy, has met its primary endpoint.
SOTIO and Cytune Pharma, members of the PPF Group, announce the first dosing of cancer patients with SO-C101, a superagonist fusion protein of interleukin IL-15.
Novartis, Amgen and Banner Alzheimer's Institute have decided to halt the clinical programme with BACE1 inhibitor CNP520 (umibecestat) for the prevention of Alzheimer's disease.
ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive Week 48 results from its phase III TANGO study.
ViiV Healthcare has commenced a trial to identify and assess approaches for implementing its once-monthly injectable treatment for HIV into clinical practice.
Ipsen and Servier announced preliminary data from the Phase 1/2 study of the investigational use of liposomal irinotecan (ONIVYDE) in combination with 5- fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in study patients with previously untreated metastatic pancreatic ductal adenocarcinoma cancer (PDAC) at the ESMO 21st World Congress on Gastrointestinal Cancer in Barcelona, Spain, 3–6 July 2019.
BiondVax Pharmaceuticals said that it has enrolled the first participant in the second cohort of a phase 3 trial of its M-001 universal flu vaccine candidate.
Pfizer and Sangamo Therapeutics have announced that an investigational SB-525 hemophilia A gene therapy has showed a sustained increased factor VIII (FVIII) levels in phase 1/2 Alta study.
VALBIOTIS announced positive results (topline data) for the Phase IIA study of VALEDIA (active substance: TOTUM-63), which evaluated this product's efficacy in a prediabetic population, compared to placebo.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.